Related Experiment Video

Updated: Aug 2, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention

A Callahan1

  • 1Stroke Service, Centennial Medical Center, Nashville, Tennessee, USA.

The American Journal of Cardiology
|October 12, 2001
PubMed

Insights

Statin therapy may reduce stroke risk, even in individuals without coronary artery disease. The SPARCL trial investigates aggressive lipid-lowering for stroke prevention in diverse patient groups.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Cerebrovascular disease is a major cause of disability, with strokes occurring frequently.
  • Statins lower lipids and have shown stroke incidence reduction in coronary artery disease patients.
  • Current statin trials exclude many stroke patients, limiting generalizability.

Purpose of the Study:

  • To prospectively evaluate aggressive lipid-lowering therapy's benefits on cerebrovascular events.
  • To assess statin efficacy in patients with prior stroke or transient ischemic attack but no coronary artery disease.

Main Methods:

  • The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial.
  • Prospective evaluation of aggressive lipid-lowering therapy.
  • Focus on patients with prior stroke/TIA and no history of coronary artery disease.

Main Results:

  • Landmark lipid-lowering trials indicate statins reduce ischemic stroke incidence.
  • A meta-analysis reported approximately 30% reduction in cerebrovascular disease incidence with statins.
  • Statin studies have primarily focused on patients with existing coronary artery disease.

Conclusions:

  • Aggressive lipid-lowering with statins may benefit a broader stroke population.
  • The SPARCL trial aims to provide crucial data for stroke prevention strategies.
  • Further research is needed to confirm statin efficacy in non-coronary artery disease stroke patients.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique07:34

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...